This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M05.9 | Special Copayment Reduction: V223 (severe intractable disease, 5 years) |
| B. Synonyms | None (seropositive RA, classification undetermined) |
| C. Adult onset | Adult onset very high — seropositive RA presents almost without exception in adults (40s–70s). It is a provisional classification code, and reclassification after confirmed diagnosis is the rule. |
| 1. History | See main text |
| 2. Causes | See main text |
| 3. Genetics | See main text |
| 4. General epidemiology | See main text |
| 5. Pathophysiology | See main text |
| 6. Symptoms | See main text |
| 7. Signs | See main text |
| 8. Screening | See main text |
| 9. Diagnosis | See main text |
| 10. Treatment | See main text |
| 11. Prognosis | See main text |
| 12. Prevention | See main text |
| 13. References | See main text |
Rheumatoid arthritis (RA) was named by Garrod in 1858, and the treatment paradigm developed with the introduction of corticosteroids in the 1940s-50s, the establishment of MTX in the 1980s, and the biologic revolution of the 2000s. The joint ACR/EULAR classification criteria were established in 2010.
M05.9 is a provisional code for cases in which seropositive RA has been confirmed but the specific subtype among M05.0–M05.8 has not been identified. The rule is to reclassify into a specific subtype promptly.
The cause of RA is the combined action of genetic predisposition such as the HLA-DRB1 shared epitope, PTPN22, and PADI4; environmental factors such as smoking and periodontal infection; and breakdown of immune tolerance to citrullinated autoantigens. TNF-α, IL-1β, IL-6, and IL-17 are the main inflammatory cytokines.
Carrying the HLA-DRB1 shared epitope (DRB1*04:01, *04:04, *01:01) increases the risk of ACPA-positive RA several-fold. PTPN22 R620W, PADI4 (East Asians), STAT4, CTLA4, and CCR6 are susceptibility genes.
RA prevalence is 0.5-1% worldwide and about 0.7-1% in Korea. It is 2-3 times more common in women than in men and occurs most often in the 40s-60s. Prognosis has improved markedly since the introduction of biologics and JAK inhibitors.
ACPA/RF formation in the preclinical stage → synovial deposition of immune complexes and complement activation → chronic synovial inflammation (TNF-α, IL-1β, IL-6, IL-17) → RANKL-mediated osteoclast activation (bone erosion) → cartilage loss by MMPs.
Same as the symptoms of M05.8. Polyarticular symmetric arthritis, morning stiffness, joint swelling and tenderness, and systemic symptoms occur.
RF-positive and/or ACPA-positive. Elevated CRP/ESR. Synovial thickening confirmed by joint ultrasound or MRI. M05.9 is a provisional code used before specific subtype classification has been made.
If there is a family history of RA, morning stiffness, or symmetric small-joint swelling, perform RF, ACPA, CRP, and CBC. Prompt referral to rheumatology to establish the final classification and treatment plan.
Seropositive RA is confirmed by the 2010 ACR/EULAR classification criteria (total score of 6 or more) plus RF or ACPA positivity. Further evaluation attempts subtype classification into M05.0–M05.8, and the case is reclassified into a specific subtype. Exclude infectious arthritis, reactive arthritis, psoriatic arthritis, SLE, gout, etc.
T2T principle: Target clinical remission by DAS28. csDMARD: MTX 15-25 mg/week (first line). bDMARD: anti-TNF (etanercept, adalimumab, etc.), abatacept, rituximab, tocilizumab/sarilumab. tsDMARD: JAK inhibitors (tofacitinib, baricitinib, upadacitinib). Steroids are used at low dose for a short period when inducing remission.
Since the introduction of biologics, functional outcomes and mortality in RA have improved markedly. Early aggressive treatment (window of opportunity) is key to determining long-term prognosis. Poor prognostic factors: high ACPA/RF titers, polyarticular involvement, early bone erosion.
Smoking cessation is the key to preventing ACPA-positive RA. Prevent joint damage with early diagnosis and aggressive DMARD treatment. Tuberculosis screening is essential before starting biologics. Pneumococcal, influenza, and herpes zoster vaccinations are recommended.